Taysha Gene Therapies Proposes Public Offering of Stock and Warrants - June 2024

DALLAS, June 25, 2024 – Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotech company devoted to the development of adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), announced the initiation of an underwritten public offering. This offering aims to raise up to $75 million through the sale of shares of its common stock and, for certain investors who prefer, pre-funded warrants to purchase its common stock. All securities in this offering will be provided by Taysha. Additionally, the company plans to grant underwriters a 30-day option to purchase up to an extra 15% of the shares offered, under identical terms and conditions, including shares underlying the pre-funded warrants. The completion and size of the offering are contingent upon market conditions, and there is no guarantee of its finalization or terms.

Jefferies and Goldman Sachs & Co. LLC are leading the offering as joint book-running managers, with Cantor also participating as a book-running manager.

The securities offered in this public offering are covered by a shelf registration statement, which Taysha filed with the Securities and Exchange Commission (SEC) on October 5, 2021. The SEC declared this statement effective on October 14, 2021. The offering will proceed solely based on a written prospectus and prospectus supplement, both of which are part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus will be filed with the SEC and made available on the SEC's website.

Taysha Gene Therapies is a company specializing in the development of AAV-based gene therapies aimed at treating severe monogenic diseases affecting the CNS. Their lead clinical program, TSHA-102, focuses on Rett syndrome, a rare neurodevelopmental disorder that currently lacks approved disease-modifying treatments addressing its genetic cause. Taysha's goal is to create transformative therapies that meet significant unmet medical needs and substantially improve the lives of patients and their caregivers.

The company's management team brings a wealth of experience in gene therapy development and commercialization. Taysha leverages this expertise, along with its manufacturing process and a clinically and commercially validated AAV9 capsid, to swiftly advance treatments from research to clinical application.